Biomarker can exclude acute kidney injury
Data presented at the 24th AKI & CRRT conference, suggest that the kidney function marker pro-enkephalin (penKid) is capable to rule out acute kidney injury (AKI) with a single measurement.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
Researchers target neuroblastoma with ALK-ADC
/in News/by Thomas GabrielczykResearchers at Celldex Therapeutics, Inc and Nerviano Medical Science Srl report elimination of the most common childhood cancer by an ADC in xenografted mice expressing either wild-type or mutated ALK.
AMR: Germany set to invest 39m into CARB-X
/in News/by Thomas GabrielczykGlobal antibacterial innovation network CARB-X announced during an AMR business conference in Berlin that Germany has joined the CARB-X partnership.
AstraZeneca partners with Seres Therapeutics
/in News/by Thomas GabrielczykUnder a three-year agreement, British pharma giant AstraZeneca plc pays 20m and R&D costs to Seres Therapeutics Inc, which will identify patterns in the microbiome predicting therapy response to cancer […]
Small-molecule acts as broad-band influenza entry blocker
/in News/by Thomas GabrielczykResearchers at Janssen Pharmaceutical Companies of Johnson & Johnson in Leiden have developed a small molecule antibody mimic, that prevents entry of multiple influenza virus serotypes.
Seventure starts second microbiome-focussed fund
/in News/by Thomas GabrielczykSeventure Partners has announced the first close of its second microbiome fund designed to put 200m in 20 companies developing microbiome-based health solutions.
EMA approves eight meds for market
/in News/by Thomas GabrielczykThe EMAs human medicines committee (CHMP) has recommended eight medicines for approval in its last meeting in London, two thereof orphan medicines. Three got conditional marketing authorisation.
Genfit set to raise $100m in Nasdaq IPO
/in News/by Thomas GabrielczykFrench Genfit SA has registered at SEC for an Nasdaq IPO of ADS in conjunction with private placements in Europe and the US.
Targeting NFkappaB protects tendons from injury
/in News/by Thomas GabrielczykResearchers from the UK and the US have prevented tendon injury and degeneration by simply blocking a key signalling pathway in inflammation.
Anaveon bags CHF35m series A financing
/in News/by Thomas GabrielczykUniversity Zurich spin-off Anaveon AG announced it will proceeds from its financing round to push development of its preclinical IL-2-receptor agonist.